BullBD Old Apps Site
Home
Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

BXPHARMA

All Eps Dividend Board Agm Q1 Q2 Q3

BXPHARMA 05-Sep-2021

(Continuation news of BXPHARMA): As anticipated, the Company and the Vendor will now seek to execute the Share Purchase Agreement. Further announcements will be made in due course. (end)

BXPHARMA 05-Sep-2021

Refer to their earlier news disseminated by DSE on 24.01.2021 regarding proposed acquisition of a majority stake in Sanofi Bangladesh Limited, the Company has further informed that the Company's proposed acquisition of a majority stake in Sanofi Bangladesh Limited ("Sanofi Bangladesh") has been approved by the Foreign Exchange Investment Department of Bangladesh Bank. (cont.)

BXPHARMA 02-May-2021

(Continuation news of BXPHARMA) as Income from Vaccine Distribution: under the head Other Income. This is non-incurring one off contract and any future earning from this source is dependent on the delivery of the committed quantity of vaccine under the agreement (end)

BXPHARMA 02-May-2021

(Continuation news of BXPHARMA) delivered 5 million vaccines during the reported quarter. As per agreement, the Company is to receive fees for import, storage and delivery of the vaccine to the GOB warehouses across the country. A net amount of BDT. 383.70 million after deduction of related expenses from fees, has been reported (Cont-3)

BXPHARMA 02-May-2021

(Continuation news of BXPHARMA) the organic growth of business and hence the profit, part of this attributable to the income from Vaccine distribution and increased cash incentive from export. They also informed that they have entered into a tripartite agreement with the Government of Bangladesh (GOB) and the Serum Institute of India Pvt. Ltd. (SII), for the supply of 30 million doses of Oxford University-AstraZenca SARS-CoV-2 vaccine, AZD1222, in Bangladesh. The Company (Cont-2)

BXPHARMA 02-May-2021

(Q3 Un-audited): Consolidated EPS was Tk. 3.28 for January-March 2021 as against Tk. 2.02 for January-March 2020; Consolidated EPS was Tk. 8.23 for July 2020-March 2021 as against Tk. 5.84 for July 2019-March 2020. Consolidated NOCFPS was Tk. 9.05 for July 2020-March 2021 as against Tk. 9.83 for July 2019-March 2020. Consolidated NAV per share was Tk. 79.73 as on March 31, 2021 and Tk. 77.88 as on March 31, 2020. The company has informed that increased in EPS predominantly from (Cont-1)

BXPHARMA 22-Apr-2021

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Corporation has informed that a meeting of the Board of Directors will be held on April 29, 2021 at 2:30 PM to consider, among others, un-audited financial statements of the Corporation for the Third Quarter (Q3) period ended on March 31, 2021.

BXPHARMA 28-Jan-2021

(Q2 Un-audited): Consolidated EPS was Tk. 2.54 for October-December 2020 as against Tk. 1.89 for October-December 2019; Consolidated EPS was Tk. 4.95 for July-December 2020 as against Tk. 3.83 for July-December 2019. Consolidated NOCFPS was Tk. 4.91 for July-December 2020 as against Tk. 9.14 for July-December 2019. Consolidated NAV per share was Tk. 76.45 as on December 31, 2020 and Tk. 75.66 as on December 31, 2019.

BXPHARMA 24-Jan-2021

(Cont. News of BXPHARMA): It is anticipated that the Proposed Transaction will be completed within the next three to nine months. If the Proposed Transaction is not approved by the Foreign Exchange Investment department of Bangladesh Bank, or has not completed by 20 October 2021, Sanofi would be able to withdraw in which case the Company's commitment would lapse and the Proposed Transaction would not proceed. (End)

BXPHARMA 24-Jan-2021

(Cont. News of BXPHARMA): The base-price consideration of Pound 35.5 million is subject to deduction for the net financial debt and adjustments for short or excess over an agreed normative working capital at the closing date. The final consideration, which may be up to a maximum of Pound 40 million, would be paid in cash on completion of the Proposed Transaction, from a combination of the Company's own cash resources and additional debt. (Cont.3)

Previous Next page